News and Trends 28 Jul 2022 Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 First patient receives new immunotherapy drug for HIV in clinical trial A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 AI being used to perform molecular analysis of biopsies from bowel disease patients Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […] July 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Cancer therapeutics company’s double win with $25M funding, and appointment of new board member An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Evotec completes acquisition of Rigenerand An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Funding doubled for company working on breakthrough auto-immune disease therapeutics A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […] June 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Drug for childhood arthritis gets expanded approvals in the EU A drug that can reduce the risk of flare and disease activity in children with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) has been approved based on data from a clinical trial. The JUNIPERA trial, showing that Cosentyx (secukinumab) reduced the risk of flare and disease activity compared to placebo over two years in pediatric patients with […] June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Watch: Antibody Analytics opens new health sciences center A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of Scotland’s authorities on immunology, officially cut the ribbon on its new health sciences research center. The unveiling of the new Antibody Analytics Discovery Centre, funded […] June 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Study reveals progress for those with hepatitis B A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Evaxion Biotech picks candidate for lung cancer trial A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate for an upcoming clinical trial for patients with advanced lung cancer. Evaxion Biotech selected EVX-03 within its DNA technology platform to target a new indication based on what it said are very encouraging results from pre-clinical studies. EVX-03 is optimized […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email